Clearside Biomedical, Inc. (CLSD)

Market Cap	95.64M
Revenue (ttm)	8.23M
Net Income (ttm)	-32.49M
Shares Out	74.72M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	179,777
Open	1.330
Previous Close	1.320
Day's Range	1.260 - 1.450
52-Week Range	0.650 - 2.120
Beta	2.33
Analysts	Strong Buy
Price Target	5.00 (+293.7%)
Earnings Date	May 9, 2024

About CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 2, 2016
• Employees: 30
• Stock Exchange: NASDAQ
• Ticker Symbol: CLSD

Financial Performance

In 2023, CLSD's revenue was $8.23 million, an increase of 519.89% compared to the previous year's $1.33 million. Losses were -$32.49 million, -1.40% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for CLSD stock is "Strong Buy." The 12-month stock price forecast is $5.0, which is an increase of 293.70% from the latest price.

Price Target

$5.0

(293.70% upside)

Analyst Consensus: Strong Buy